Core Points - Lisata Therapeutics has received a new composition of matter patent for certepetide, extending IP protection until March 2040, with potential for further extension [1][2] - The patent secures exclusive rights to certepetide, preventing others from manufacturing or selling the drug, thus significantly enhancing the company's IP portfolio [2][3] - The CEO of Lisata highlighted that this patent milestone boosts the value of certepetide and the company, delaying generic competition for nearly two decades and supporting commercialization efforts [3] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [5] - Certepetide is designed to enhance the delivery of anti-cancer drugs to solid tumors by activating a novel uptake pathway, showing promise in improving treatment efficacy [4][5] - The company has established significant partnerships and expects to announce multiple milestones in the next 1.5 years, with sufficient capital projected to fund operations into Q4 2026 [5]

Core Insights - The ASCEND Phase 2b trial shows promising preliminary data for certepetide in treating metastatic pancreatic cancer, with positive signals in progression-free survival and objective response rates compared to placebo [1][2][6] - Cohort B data supports the findings from Cohort A, indicating a treatment effect and an attractive safety profile for certepetide [1][6][8] - Full study data from both cohorts is expected later this year, which may provide further insights into the efficacy of certepetide [7] Study Design and Results - The ASCEND trial is a double-blind, randomized, placebo-controlled study involving 158 patients, comparing standard-of-care gemcitabine and nab-paclitaxel with or without certepetide [3] - Cohort A utilized a single dose of 3.2 mg/kg of certepetide, while Cohort B included an additional dose administered four hours later [3] - Preliminary results from Cohort B indicate a six-month progression-free survival of 60.8% for the certepetide group versus 25% for the placebo group, with median progression-free survival of 7.5 months compared to 4.7 months [5] Clinical Significance - The addition of certepetide resulted in a clinically meaningful improvement in both progression-free survival and objective response rates for patients with metastatic pancreatic ductal adenocarcinoma [6] - The objective response rate was 45.2% for the certepetide group compared to 19% for the placebo group, and median overall survival was 10.32 months versus 9.23 months [5] Industry Context - Pancreatic cancer has a poor prognosis, being the sixth leading cause of cancer mortality globally, with a five-year survival rate of only 13%, highlighting the need for new treatment options [9] - Certepetide is designed to enhance the delivery of anti-cancer drugs to solid tumors and has shown favorable safety and tolerability in clinical trials [12][13]

Targeted Therapy Delivered Corporate Presentation | May 8, 2025 Nasdaq: LSTA www.lisata.com © Lisata Therapeutics, Inc. 2025. All rights reserved. Disclosure Forward-looking statements advisory This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, futur ...